Last reviewed · How we verify
ELETRIPTAN HYDROBROMIDE
Eletriptan Hydrobromide is a marketed drug primarily indicated for the acute treatment of migraine. Its key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | ELETRIPTAN HYDROBROMIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
- Acute treatment of migraine
Common side effects
- Nausea
- Dizziness
- Somnolence
- Asthenia
- Paresthesia
- Flushing/feeling of warmth
- Chest tightness/pain/pressure
- Abdominal pain/discomfort/stomach pain/cramps/pressure
- Dry mouth
- Dyspepsia
- Dysphagia throat tightness/difficulty swallowing
- Headache
Drug interactions
- Ergotamine-containing or ergot-type medications (e.g., dihydroergotamine [DHE], methysergide)
- Other 5-HT1B/1D agonists
- Potent CYP3A4 inhibitors
- Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs)
Key clinical trials
- Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury (PHASE1, PHASE2)
- Eletriptan Pharmacokinetics In Korean Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |